ECSP045349A - Formuilaciones liquidas de baja dosis de entecavir y uso - Google Patents

Formuilaciones liquidas de baja dosis de entecavir y uso

Info

Publication number
ECSP045349A
ECSP045349A EC2004005349A ECSP045349A ECSP045349A EC SP045349 A ECSP045349 A EC SP045349A EC 2004005349 A EC2004005349 A EC 2004005349A EC SP045349 A ECSP045349 A EC SP045349A EC SP045349 A ECSP045349 A EC SP045349A
Authority
EC
Ecuador
Prior art keywords
entecavir
liquid
low dose
formulated
present
Prior art date
Application number
EC2004005349A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045349A publication Critical patent/ECSP045349A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona composiciones farmacéuticas líquidas que tienen una baja dosis de entecavir. En una modalidad de la presente invención, la composición líquida de entecavir es una composición lista para usar que está formulada para ser estable y de sabor agradable. En una segunda modalidad de la presente invención, la composición líquida de entecavir se formula de una composición en polvo en el momento de uso. Las composiciones de baja dosis de entevacir también pueden incluir por lo menos un componente seleccionado de edulcorante, conservador, agente saborizante, agente amortiguador o combinaciones de estos. Las composiciones líquidas de entevacir también pueden formularse en combinación con otros agentes farmacéuticamente activos.
EC2004005349A 2002-04-08 2004-10-08 Formuilaciones liquidas de baja dosis de entecavir y uso ECSP045349A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37067402P 2002-04-08 2002-04-08

Publications (1)

Publication Number Publication Date
ECSP045349A true ECSP045349A (es) 2005-01-03

Family

ID=29250568

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005349A ECSP045349A (es) 2002-04-08 2004-10-08 Formuilaciones liquidas de baja dosis de entecavir y uso

Country Status (22)

Country Link
US (1) US20030190334A1 (es)
EP (1) EP1492510A4 (es)
JP (1) JP2005528389A (es)
KR (1) KR20040099403A (es)
CN (1) CN1319517C (es)
AR (1) AR039388A1 (es)
AU (1) AU2003226259A1 (es)
BR (1) BR0309057A (es)
CA (1) CA2481092A1 (es)
EA (1) EA008102B1 (es)
EC (1) ECSP045349A (es)
HR (1) HRP20040893A2 (es)
MX (1) MXPA04009735A (es)
MY (1) MY131488A (es)
NO (1) NO20044451L (es)
NZ (1) NZ535535A (es)
PE (1) PE20040324A1 (es)
PL (1) PL372322A1 (es)
RS (1) RS88404A (es)
TW (1) TWI275392B (es)
WO (1) WO2003086367A1 (es)
ZA (1) ZA200407672B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296769B2 (en) 2011-08-16 2016-03-29 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN1732944B (zh) * 2005-09-02 2013-05-08 海南中和药业有限公司 恩替卡韦分散片及其制备方法
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
RU2381807C1 (ru) * 2008-07-18 2010-02-20 Алексей Глебович Одинец Противовирусное средство
CN101869569A (zh) * 2009-04-21 2010-10-27 李迪 即用型恩替卡韦组合物
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
CN102908312B (zh) * 2011-11-10 2014-06-04 陈小花 抗乙肝病毒液体组合物
US8517850B1 (en) * 2012-12-11 2013-08-27 Cobra Golf Incorporated Golf club grip with device housing
KR101462018B1 (ko) * 2013-04-01 2014-11-19 썬시스템즈(주) 엔테카비르 함유 구강 붕해형 필름제제
CN103301071A (zh) * 2013-06-03 2013-09-18 北京阜康仁生物制药科技有限公司 一种稳定的恩替卡韦无糖型颗粒剂及其制备方法
RU2016107827A (ru) * 2013-08-06 2017-09-14 Донг Кук Фарм. Ко., Лтд Микросферы энтекавира и фармацевтическая композиция для парентерального введения, содержащая их
WO2015194923A1 (ko) * 2014-06-20 2015-12-23 주식회사 씨티씨바이오 엔테카비르를 유효성분으로 포함하는 약학 제제 및 이의 제조방법
CN104083374A (zh) * 2014-07-18 2014-10-08 石家庄创建医药科技有限公司 一种恩替卡韦口服液组合物
CN109984996B (zh) * 2018-01-02 2022-01-18 扬子江药业集团有限公司 恩替卡韦口服溶液及其制备方法
CN108434096A (zh) * 2018-06-20 2018-08-24 广州大光制药有限公司 一种恩替卡韦口服溶液及其制备方法
CN112334151A (zh) * 2018-06-29 2021-02-05 学校法人同志社 包含恩利卡生的制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
CA2359110A1 (en) * 1999-01-12 2000-07-20 Ronald James Boon Combination of hepatitis b vaccine with antiviral agents
ATE312613T1 (de) * 2000-02-29 2005-12-15 Bristol Myers Squibb Co Niedrig dosierte entecavir formulierung und deren verwendung
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296769B2 (en) 2011-08-16 2016-03-29 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate

Also Published As

Publication number Publication date
AU2003226259A1 (en) 2003-10-27
CA2481092A1 (en) 2003-10-23
US20030190334A1 (en) 2003-10-09
ZA200407672B (en) 2005-10-12
JP2005528389A (ja) 2005-09-22
EA008102B1 (ru) 2007-04-27
PE20040324A1 (es) 2004-05-29
WO2003086367A1 (en) 2003-10-23
HRP20040893A2 (en) 2005-02-28
PL372322A1 (en) 2005-07-11
MY131488A (en) 2007-08-30
EP1492510A4 (en) 2006-01-11
NZ535535A (en) 2006-09-29
NO20044451L (no) 2004-11-04
EA200401298A1 (ru) 2005-02-24
CN1319517C (zh) 2007-06-06
EP1492510A1 (en) 2005-01-05
AR039388A1 (es) 2005-02-16
TW200306840A (en) 2003-12-01
BR0309057A (pt) 2005-02-01
KR20040099403A (ko) 2004-11-26
CN1658844A (zh) 2005-08-24
MXPA04009735A (es) 2005-01-11
RS88404A (sr) 2006-12-15
TWI275392B (en) 2007-03-11

Similar Documents

Publication Publication Date Title
ECSP045349A (es) Formuilaciones liquidas de baja dosis de entecavir y uso
WO2002078627A3 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
UY26716A1 (es) Emulsiones estables para productos cosméticos.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
ES2721899T3 (es) Composiciones farmacéuticas que comprenden fentanilo para su administración intranasal
ATE554792T1 (de) Stabiles wachstumshormon-flüssigformulierung
HRP20050510A2 (en) Microbicide substances
DE50109650D1 (de) Topische behandlung bei der mastalgie
HUP0301506A2 (hu) Gyógyászati készítmények nedves hámfelületek fájdalmas, gyulladásos vagy fekélyes állapotai, így például nyálkahártyagyulladás, szájgyulladás és behcet-tünetcsoport kezelésére
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.
CA2494473A1 (en) Stabilized protein compositions for topical administration and methods of making same
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
MXPA04004907A (es) Composiciones de acetaminofen.
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica
WO2004087105A8 (en) Combination formulations of platinum agents and fluoropyrimidines
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
WO2004062671A3 (en) Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
BR0108732A (pt) Composição farmacêutica para a prevenção e tratamento da progressão da fibrose e cirrose hepática, seu uso e método para a prevenção e tratamento da fibrose e cirrose hepática
ES2147796T3 (es) Composicion para el tratamiento o la prevencion del herpes.
BR0301968A (pt) Misturas eutéticas ternárias e quaternárias constituìdas por substâncias anestésicas locais, seu emprego no preparo de composições farmacêuticas e seu uso em anestesia e analgesia tópica
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола